ctDNA kinetics throughout first-line AI and palbociclib using a tumor-informed structural variant-based ctDNA assay: Retrospective analysis of PADA-1 samples.

Journal of Clinical Oncology 2026

View at publisher
Authors: Luc Cabel, Véronique D’Hondt, Thomas Bachelot, Patrick Soulie, Chantal Bernard-Marty, Pascal Boucher, Clara Guyonneau, Anne Pradines, Völundur Hafstad, Céline Callens, Sofia Birkeälv, Miguel Alcaide Torres
+4 more Jennifer Yen, Karen Howarth, Frédérique Berger, Francois Clement Bidard
DOI: 10.1200/jco.2026.44.16_suppl.3050
Cited by: 1

Abstract

3050 Background: With standard assays (Limit of Detection [LoD95] at or >100 PPM), most patients with ER+/HER2- mBC show ctDNA "clearance" within a few weeks after initiating first- line AI+CDK4/6i, with ctDNA becoming detectable again only at or shortly before progression. To gain a more comprehensive view of ctDNA kinetics in response to therapy, we analyzed serial plasma samples from PADA-1 using a tumor-informed assay with a 100-1,000-fold higher sensitivity (LoD95

Fields of Study & Subjects

Cancer Genomics and Diagnostics Advanced Breast Cancer Therapies PARP inhibition in cancer therapy

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
3050–3050
Publication date
27 May 2026
Language
EN